company background image
ARX

Aroa Biosurgery ASX:ARX Stock Report

Last Price

AU$1.23

Market Cap

AU$421.8m

7D

3.4%

1Y

50.0%

Updated

27 Jan, 2023

Data

Company Financials +

ARX Stock Overview

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

ARX fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 59% below our estimate of its fair value

Earnings are forecast to grow 88.13% per year

Risk Analysis

No risks detected for ARX from our risk checks.

My Notes

New

Notes are coming soon

Aroa Biosurgery Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aroa Biosurgery
Historical stock prices
Current Share PriceAU$1.23
52 Week HighAU$1.25
52 Week LowAU$0.61
Beta0.62
1 Month Change13.36%
3 Month Change43.02%
1 Year Change50.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-8.89%

Recent News & Updates

Recent updates

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Shareholder Returns

ARXAU BiotechsAU Market
7D3.4%-1.4%0.6%
1Y50.0%11.8%3.5%

Return vs Industry: ARX exceeded the Australian Biotechs industry which returned 15.9% over the past year.

Return vs Market: ARX exceeded the Australian Market which returned 5.4% over the past year.

Price Volatility

Is ARX's price volatile compared to industry and market?
ARX volatility
ARX Average Weekly Movement3.8%
Biotechs Industry Average Movement9.1%
Market Average Movement8.6%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: ARX is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ARX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aBrian Wardhttps://aroabio.com

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company’s products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Aroa Biosurgery Limited Fundamentals Summary

How do Aroa Biosurgery's earnings and revenue compare to its market cap?
ARX fundamental statistics
Market CapAU$421.75m
Earnings (TTM)-AU$1.56m
Revenue (TTM)AU$46.66m

9.0x

P/S Ratio

-270.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARX income statement (TTM)
RevenueNZ$51.17m
Cost of RevenueNZ$9.71m
Gross ProfitNZ$41.46m
Other ExpensesNZ$43.17m
Earnings-NZ$1.71m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Jan 31, 2023

Earnings per share (EPS)-0.005
Gross Margin81.02%
Net Profit Margin-3.34%
Debt/Equity Ratio0%

How did ARX perform over the long term?

See historical performance and comparison